Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures

BACKGROUND: Small cell lung cancer (SCLC) is usually diagnosed in the advanced stage. It has a very poor prognosis, with no advancements in therapy in the last few decades. A recent phase 1 clinical study, using an antibody-drug conjugate directed against DLL3, showed promising results. A prerequisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Brcic, Luka, Kuchler, Christian, Eidenhammer, Sylvia, Pabst, Daniela, Quehenberger, Franz, Gazdar, Adi F., Popper, Helmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528329/
https://www.ncbi.nlm.nih.gov/pubmed/31109352
http://dx.doi.org/10.1186/s13000-019-0827-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528329/
https://www.ncbi.nlm.nih.gov/pubmed/31109352
http://dx.doi.org/10.1186/s13000-019-0827-z

Ejemplares similares